{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:26:36Z","timestamp":1767068796502,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10637-025-01592-x","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:56:54Z","timestamp":1764997014000},"page":"1235-1246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-953X","authenticated-orcid":false,"given":"Yasutoshi","family":"Kuboki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Kmieciak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Slade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosho","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Kawasumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"unstructured":"Global Cancer Observatory (GCO) Global Cancer Observatory Japan Population Factsheet: Statistics at a glance, 2022. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/392-japan-fact-sheet.pdf. Accessed 26 June 2007.","key":"1592_CR1"},{"key":"1592_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/ace.2018.08.01","volume":"2","author":"T Matsuda","year":"2018","unstructured":"Matsuda T, Saika K (2018) Cancer burden in Japan based on the latest cancer statistics: need for evidence-based cancer control programs. Ann Cancer Epidemiol 2:2. https:\/\/doi.org\/10.21037\/ace.2018.08.01","journal-title":"Ann Cancer Epidemiol"},{"key":"1592_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925938","volume":"12","author":"T Mizuno","year":"2022","unstructured":"Mizuno T, Katsuya Y, Sato J et al (2022) Emerging PD-1\/PD-L1 targeting immunotherapy in non-small cell lung cancer: current status and future perspective in Japan, US, EU, and China. Front Oncol 12:925938. https:\/\/doi.org\/10.3389\/fonc.2022.925938","journal-title":"Front Oncol"},{"key":"1592_CR4","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"1592_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT (2018) Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 118:9\u201316. https:\/\/doi.org\/10.1038\/bjc.2017.434","journal-title":"Br J Cancer"},{"key":"1592_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A (2018) Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J 24:47\u201353. https:\/\/doi.org\/10.1097\/PPO.0000000000000303","journal-title":"Cancer J"},{"key":"1592_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00483","volume":"10","author":"TA Leal","year":"2024","unstructured":"Leal TA, Dasgupta A, Latremouille-Viau D et al (2024) Real-world treatment patterns and clinical outcomes after platinum-doublet chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a multiregional chart review in the United States, Europe, and Japan. JCO Glob Oncol 10:e2300483. https:\/\/doi.org\/10.1200\/GO.23.00483","journal-title":"JCO Glob Oncol"},{"key":"1592_CR8","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T et al (2018) Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem 61:9889\u20139907. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01187","journal-title":"J Med Chem"},{"key":"1592_CR9","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker EL, Sanseviero E, Karmokar A et al (2024) The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat Commun 15:1700. https:\/\/doi.org\/10.1038\/s41467-024-45996-4","journal-title":"Nat Commun"},{"key":"1592_CR10","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","volume":"82","author":"Z Wilson","year":"2022","unstructured":"Wilson Z, Odedra R, Wallez Y et al (2022) ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res 82:1140\u20131152. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2997","journal-title":"Cancer Res"},{"key":"1592_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K et al (2024) Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest 134:e175369. https:\/\/doi.org\/10.1172\/JCI175369","journal-title":"J Clin Invest"},{"key":"1592_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005041","volume":"10","author":"M Kwon","year":"2022","unstructured":"Kwon M, Kim G, Kim R et al (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer 10:e005041. https:\/\/doi.org\/10.1136\/jitc-2022-005041","journal-title":"J Immunother Cancer"},{"key":"1592_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim R, Kwon M, An M et al (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol 33:193\u2013203. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.009","journal-title":"Ann Oncol"},{"key":"1592_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse B, Pons-Tostivint E, Park K et al (2024) Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med 30:716\u2013729. https:\/\/doi.org\/10.1038\/s41591-024-02808-y","journal-title":"Nat Med"},{"key":"1592_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK et al (2022) Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 17:e0264138. https:\/\/doi.org\/10.1371\/journal.pone.0264138","journal-title":"PLoS One"},{"key":"1592_CR16","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1158\/1538-7445.Am2018-5603","volume":"78","author":"E Helman","year":"2018","unstructured":"Helman E, Artieri C, Vowles JV et al (2018) Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research. Cancer Res 78:5603\u20135603. https:\/\/doi.org\/10.1158\/1538-7445.Am2018-5603","journal-title":"Cancer Res"},{"key":"1592_CR17","doi-asserted-by":"publisher","first-page":"TPS9161","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9161","volume":"41","author":"B Besse","year":"2023","unstructured":"Besse B, Castro G, Felip E et al (2023) LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy. J Clin Oncol 41:TPS9161. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS9161","journal-title":"J Clin Oncol"},{"key":"1592_CR18","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","volume":"27","author":"ST Kim","year":"2021","unstructured":"Kim ST, Smith SA, Mortimer P et al (2021) Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer. Clin Cancer Res 27:4700\u20134709. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0251","journal-title":"Clin Cancer Res"},{"key":"1592_CR19","doi-asserted-by":"publisher","first-page":"viii135","DOI":"10.1093\/annonc\/mdy279.401","volume":"29","author":"M Krebs","year":"2018","unstructured":"Krebs M, Lopez J, El-Khoueiry A et al (2018) Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. Ann Oncol 29:viii135. https:\/\/doi.org\/10.1093\/annonc\/mdy279.401","journal-title":"Ann Oncol"},{"key":"1592_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1124\/dmd.117.077776","volume":"45","author":"BC Jones","year":"2017","unstructured":"Jones BC, Markandu R, Gu C, Scarfe G (2017) CYP-mediated sulfoximine deimination of AZD6738. Drug Metab Dispos 45:1133\u20131138. https:\/\/doi.org\/10.1124\/dmd.117.077776","journal-title":"Drug Metab Dispos"},{"key":"1592_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-021-04388-x","volume":"89","author":"BF Kiesel","year":"2022","unstructured":"Kiesel BF, Guo J, Parise RA et al (2022) Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice. Cancer Chemother Pharmacol 89:231\u2013242. https:\/\/doi.org\/10.1007\/s00280-021-04388-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"1592_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00224","volume":"10","author":"Y Guttman","year":"2019","unstructured":"Guttman Y, Nudel A, Kerem Z (2019) Polymorphism in cytochrome P450 3A4 is ethnicity related. Front Genet 10:224. https:\/\/doi.org\/10.3389\/fgene.2019.00224","journal-title":"Front Genet"},{"key":"1592_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.20892\/j.issn.2095-3941.2020.0351","volume":"18","author":"Z Gong","year":"2021","unstructured":"Gong Z, Yang Y, Zhang J, Guo W (2021) Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types. Cancer Biol Med 18:1080\u20131091. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0351","journal-title":"Cancer Biol Med"},{"doi-asserted-by":"publisher","unstructured":"Heeke AL, Pishvaian MJ, Lynce F et al (2018) Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol 2018: https:\/\/doi.org\/10.1200\/PO.17.00286","key":"1592_CR24","DOI":"10.1200\/PO.17.00286"},{"key":"1592_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00442-4","volume":"7","author":"D Wang","year":"2023","unstructured":"Wang D, Elenbaas B, Murugesan K et al (2023) Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. NPJ Precis Oncol 7:103. https:\/\/doi.org\/10.1038\/s41698-023-00442-4","journal-title":"NPJ Precis Oncol"},{"key":"1592_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown JS, O\u2019Carrigan B, Jackson SP, Yap TA (2017) Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov 7:20\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0860","journal-title":"Cancer Discov"},{"key":"1592_CR27","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz LM, Zou L (2015) Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res 21:4780\u20134785. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0479","journal-title":"Clin Cancer Res"},{"key":"1592_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo LI, Altmeyer M, Rask MB et al (2013) ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 155:1088\u20131103. https:\/\/doi.org\/10.1016\/j.cell.2013.10.043","journal-title":"Cell"},{"key":"1592_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"key":"1592_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","volume":"27","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15\u201326. https:\/\/doi.org\/10.1016\/j.ccell.2014.12.001","journal-title":"Cancer Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01592-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:25:24Z","timestamp":1767068724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01592-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jun Sato and Yuki Katsuya have no conflicts to disclose. Yasutoshi Kuboki has received grants or contracts (to the institution) from Taiho, Astellas, Eli\u00a0Lilly, Takeda, Daiichi Sankyo, Astra-Zeneca, Boehringer Ingelheim, Chugai, Genmab, Incyte, AbbVie, Amgen, Merck, Hengrui, Novartis, Ono Pharmaceutical, Noile-Immune Biotech Inc, Kyowa Kirin, and BMS; consulting fees from Incyte, Takeda, Noile-Immune Biotech Inc, Amgen, and AbbVie; honoraria from Taiho, Eli\u00a0Lilly, Takeda, Kyowa Kirin, and Amgen; and support for attending meetings and\/or travel from Amgen. Nobuaki Matsubara participated in an advisory council or committee for Janssen, Pfizer, Novartis, Astellas and AbbVie; received honoraria from Sanofi and Janssen; and received grants or funds from Janssen, Astra-Zeneca, Bayer, Roche, MSD, Taiho, Astellas, Amgen, Eisai, Eli Lilly, Takeda, Pfizer, Chugai, Seagen, AbbVie, Telix and Novartis. Hiromichi Nakajima has received honoraria from Chugai, Takeda, Pfizer, Eli Lilly, Astra-Zeneca, Ono Pharmaceutical, Sanofi\/Regeneron, and MSD; consulting fees from Terumo Corporation; grants or funds from Merck BioPharma; and notes that an immediate family member is employed by Otsuka Pharmaceutical Co., Ltd.. Takao Fujisawa has received honoraria from Amelieff and Astra-Zeneca. Takafumi Koyama has received honoraria from Chugai Pharma and Sysmex; and grants or funds from Chugai Pharma, Daiichi Sankyo RD Novare, Eli Lilly, Novartis, PACT Pharma, Boehringer Ingelheim, Astra-Zeneca, Pfizer, Takeda and Zymeworks. Aleksandra Kmieciak and Daniel Slade are employed by Astra-Zeneca, and own stocks\/shares in Astra-Zeneca. Kiyomi Iwata, Yusuke Takahashi, Masahiro Nii, Toshio Kawata, Hisashi Kawasumi are employed by Astra-Zeneca K.K.. Kosho Murayama is employed by Astra-Zeneca K.K. and owns stocks\/shares in Eisai, Astellas and Pfizer. Noboru Yamamoto has participated in an advisory council or committee for Eisai, Boehringer Ingelheim, Cmic, Chugai, Merck, Healios\u00a0K.\u00a0K., Mitsubishi Tanabe, Rakuten Medical, IQVIA, Noile-Immune Biotech, and Janssen Pharma; and received honoraria from Chugai, Daiichi Sankyo, and Eisai; and grants or funds from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, Ono\u00a0Pharmaceutical, Janssen Pharma, MSD, Merck, GlaxoSmithKline, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, Toray, Kaken, Astra-Zeneca, InventisBio, Rakuten Medical, Amgen, Bicycle Therapeutics, and Zymeworks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}